Making Better Tomorrow, Bukwang Pharmaceutical. Bukwang R&D
NEWS

Contera Pharma, a subsidiary of Bukwang, has partnership with Abzu

[July 08, 2021]

Contera Pharma, a subsidiary of Bukwang, is focused on developing new treatments for people suffering from neurological disorders. Contera Pharma and Abzu partner to design RNA therapeutics on two exclusive targets within rare neurological disorders using xAI technology. The two programs are the first precision medicine projects under the Contera Pharma CP2G-NOVA platform. As part of the Contera Pharma strategy to expand our early pipeline with internal innovative projects, the CP2G-NOVA (RNA therapeutic platform) will deliver several prog...

R&D

Contera Pharma, a subsidiary of Bukwang,

has partnership with Abzu

[July 08, 2021]

Contera Pharma, a subsidiary of Bukwang, is focused on developing new treatments for people suffering from neurological disorders. Contera...

COMPANY

Bukwang Pharmaceutical Co., Ltd. was established on October 17th, 1960 and has since continued to produce excellent medications with the aim of improving global health for the last 55 years. Since Bukwang was listed in the Korea Stock Exchange...

Conterapharma
콘테라로고.jpg

Unlocking science for treating neurological disorders

   

Discover Bukwang

PRODUCTS
|    ​Korean    |